Melanie de Boer, PhD

Gilead Sciences

Disclosure(s): Gilead Sciences: Employee, Stocks/Bonds

Poster(s):

• 2059 - Estimated Background HIV Diagnosis Rates among People Who Could Benefit from Pre-Exposure Prophylaxis (PrEP) at the Metropolitan Statistical Area (MSA) level in the United States, 2012-2019
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET